AttendMe Owl Logo
AttendMe
Evidence Evolution
RadiologyRadiology

How This Evidence Evolved

Adrenal Incidentaloma Imaging

From surgical exploration to imaging-based risk stratification and reducing unnecessary follow-up

19.5

Timeline

Signal

Early observations and pilot data that first suggested a new direction

Unenhanced CT can help characterize adrenal masses. A study of 100 patients with non-small cell lung carcinoma identified 15 adrenal masses in 13 patients. In patients receiving contrast, unenhanced images helped classify three masses as benign at 10 HU or less and three as indeterminate above 10 HU. This study addressed characterization in a lung-cancer population. Modern management combines imaging characteristics with clinical and endocrine assessment, rather than treating low attenuation as a reason to omit hormonal evaluation.
Proof

Landmark RCTs and pivotal trials that established the evidence base

Caoili and colleagues evaluated 166 adrenal masses with unenhanced CT and, for masses above 10 HU, enhanced and delayed enhanced CT. Adenoma criteria were attenuation of 10 HU or less or enhancement washout of at least 60%. The combined protocol had 98% sensitivity and 92% specificity. A chemical-shift MRI study of 38 masses in 36 patients with attenuation above 10 HU used a 20% signal-intensity decrease threshold. Sensitivity for adenoma was 67% and specificity 100%; sensitivity was 89% among masses measuring 10–30 HU. These results depend on the studied protocol and population.
Extension

Follow-up studies, subgroup analyses, and real-world validation

The 2017 ACR White Paper provides an algorithm based on patient characteristics and adrenal imaging features. ESE/ENSAT guidance was revised in 2023. Homogeneous adrenal lesions at ≤10 HU on unenhanced CT require no additional imaging independent of size. This does not remove the need for clinical and endocrine assessment. Guidance includes a 1-mg overnight dexamethasone suppression test. Lesions >4 cm with inhomogeneity or HU >20 usually warrant surgery; other lesions require multidisciplinary assessment. This separates imaging follow-up from evaluation for hormone excess.
Guidelines

Integration into clinical practice guidelines and recommendations

ESE/ENSAT recommends dedicated adrenal imaging. Homogeneous lesions ≤10 HU on unenhanced CT require no additional imaging, independent of size; this does not mean hormonal assessment can be omitted. Other lesions require expert multidisciplinary discussion. Surgery is usually chosen for lesions >4 cm that are inhomogeneous or have HU >20. Clinical and endocrine work-up includes metanephrines and an overnight dexamethasone test. Surgical decisions also depend on hormone excess, age, health and patient preference.
ACR Incidental Findings Committee
ESE/ENSAT Clinical Practice Guideline

ESE/ENSAT 2023: homogeneous ≤10 HU: no further imaging, regardless of size. Endocrine workup includes 1-mg DST. Surgery usually for >4 cm with inhomogeneity or HU >20. Discuss other lesions in a multidisciplinary expert meeting.

Now

Current standard of care and ongoing research directions

Adrenal-mass management combines imaging with endocrine and clinical assessment. ESE/ENSAT distinguishes homogeneous low-attenuation lesions needing no further imaging from other lesions requiring multidisciplinary discussion. Likelihood of malignancy, hormone excess, comorbidities, age, health and patient preference inform decisions. Balancing unnecessary investigation against missed clinically important disease remains the practical task; imaging reassurance alone does not replace endocrine assessment.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

What is the significance of the 10 HU threshold on unenhanced CT?+
ESE/ENSAT 2023 considers a homogeneous adrenal lesion measuring ≤10 HU on unenhanced CT benign, with no additional imaging required independent of size. This imaging rule does not exclude hormone excess. Clinical and endocrine assessment remains necessary, including a 1-mg overnight dexamethasone suppression test. Imaging reassurance and hormonal evaluation answer different questions.
How does CT washout analysis work for adrenal masses?+
Caoili's protocol used unenhanced CT, then contrast-enhanced and delayed enhanced CT for masses above 10 HU. Adenoma criteria were attenuation ≤10 HU or enhancement washout ≥60%. The combined protocol correctly characterized 160 of 166 masses, with 98% sensitivity and 92% specificity. These are results for the complete protocol in the studied population.
When should an adrenal incidentaloma be surgically removed?+
ESE/ENSAT 2023 states that lesions >4 cm with inhomogeneity or HU >20 usually warrant surgery. Other lesions should undergo multidisciplinary expert assessment. Decisions also depend on hormone excess, age, general health, and patient preference. Surgery is usually unnecessary for an asymptomatic, nonfunctioning unilateral mass with obvious benign imaging features.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026